The Lancet Oncology
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
✓ Free legal copy found
Preprint, hosted by LA Referencia (hdl.handle.net)
This is the authors’ own version from before peer review, so it may differ from the published paper.
Read it free at hdl.handle.net →DOI: 10.1016/s1470-2045(11)70393-x · Publisher: Elsevier BV